| 1 |
Li Z, Xu S, Shi J, Zhang Y. Pneumocystis pneumonia in a patient with diabetes mellitus: A case report. Medicine (Baltimore) 2023;102:e32290. [PMID: 36749248 DOI: 10.1097/MD.0000000000032290] [Reference Citation Analysis]
|
| 2 |
Guan N, Zhang M, Zhang M, Chen R, Xie Q, Hao C. Rituximab Treatment as Initial Therapy in Adult Patients with Minimal Change Disease. Kidney International Reports 2023. [DOI: 10.1016/j.ekir.2023.02.1070] [Reference Citation Analysis]
|
| 3 |
Wei M, Qiu Z, Li H, Lu B, Wang C, Ji L. Integrating network pharmacology approach and experimental validation to reveal the alleviation of Shenkangning capsule on chronic nephritis. J Ethnopharmacol 2022;299:115676. [PMID: 36057408 DOI: 10.1016/j.jep.2022.115676] [Reference Citation Analysis]
|
| 4 |
Liu B, Cao Y, Wang D, Zhou Y, Zhang P, Wu J, Chen J, Qiu J, Zhou J. Zhen-Wu-Tang Induced Mitophagy to Protect Mitochondrial Function in Chronic Glomerulonephritis via PI3K/AKT/mTOR and AMPK Pathways. Front Pharmacol 2021;12:777670. [PMID: 35757387 DOI: 10.3389/fphar.2021.777670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Bittner GD, Bushman JS, Ghergherehchi CL, Roballo KCS, Shores JT, Smith TA. Typical and atypical properties of peripheral nerve allografts enable novel strategies to repair segmental-loss injuries. J Neuroinflammation 2022;19. [DOI: 10.1186/s12974-022-02395-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Carter SA, Teng C, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster DJ, Coppo R, Fervenza FC, Floege J, Hladunewich MA, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Viecelli AK, Dunn L, Harris D, Johnson DW, Kerr PG, Laboi P, Ryan J, Shen JI, Ruiz L, Wang AY, Lee AHK, Ka Shun SF, Ka-Hang Tong M, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Martin A, Tong A. A Focus Group Study of Self-Management in Patients With Glomerular Disease. Kidney Int Rep 2022;7:56-67. [PMID: 35005314 DOI: 10.1016/j.ekir.2021.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Thangavel K, Sankaranarayanan A. Microorganisms in Pathogenesis and Management of Immune-Mediated Glomerulopathies. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases 2022. [DOI: 10.1007/978-981-19-4800-8_6] [Reference Citation Analysis]
|
| 8 |
Carter SA, Lightstone L, Cattran D, Tong A, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster DJ, Coppo R, Fervenza FC, Floege J, Hladunewich MA, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Anumudu S, Cho Y, Gutman T, O'Lone E, Viecelli AK, Au E, Azukaitis K, Baumgart A, Bernier-Jean A, Dunn L, Howell M, Ju A, Logeman C, Nataatmadja M, Sautenet B, Sharma A, Craig JC; SONG-GD Workshop Investigators. A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops. Clin J Am Soc Nephrol 2022;17:53-64. [PMID: 34969698 DOI: 10.2215/CJN.07840621] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Duarte I, Oliveira J, Outerelo C, Godinho I, Pereira M, Fernandes P, Jorge S, Gameiro J. Rituximab in glomerular diseases: a case series and narrative review. J Bras Nefrol 2021:S0101-28002021005081301. [PMID: 34874051 DOI: 10.1590/2175-8239-JBN-2021-0120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Cheng YJ, Cheng XY, Zhang YM, Wang F, Wang X, Meng LQ, Liu G, Cui Z, Zhao MH. Effects of hydroxychloroquine on proteinuria in membranous nephropathy. J Nephrol 2021. [PMID: 34846713 DOI: 10.1007/s40620-021-01182-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Al Mushafi A, Ooi JD, Odobasic D. Crescentic Glomerulonephritis: Pathogenesis and Therapeutic Potential of Human Amniotic Stem Cells. Front Physiol 2021;12:724186. [PMID: 34721059 DOI: 10.3389/fphys.2021.724186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Hendren E, Radhakrishnan J. ANCA Vasculitis Treatment in the Dialysis Patient: Caution Needed! Clin J Am Soc Nephrol 2021;16:1617-9. [PMID: 34750158 DOI: 10.2215/CJN.11960921] [Reference Citation Analysis]
|
| 13 |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 137] [Cited by in F6Publishing: 184] [Article Influence: 68.5] [Reference Citation Analysis]
|
| 14 |
Koirala A, Jefferson JA. Steroid Minimization in Adults with Minimal Change Disease. Glomerular Dis 2021;1:237-49. [PMID: 36751385 DOI: 10.1159/000517626] [Reference Citation Analysis]
|
| 15 |
Speer C, Altenmüller-Walther C, Splitthoff J, Nusshag C, Kälble F, Reichel P, Morath C, Zeier M, Bergner R, Schaier M. Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study. Medicine (Baltimore) 2021;100:e26733. [PMID: 34398050 DOI: 10.1097/MD.0000000000026733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Obrișcă B, Vornicu A, Jurubiță R, Achim C, Bobeică R, Andronesi A, Sorohan B, Herlea V, Procop A, Dina C, Ismail G. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol 2021;40:3285-97. [PMID: 33595739 DOI: 10.1007/s10067-021-05646-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in Membranous Nephropathy. Kidney Int Rep 2021;6:881-93. [PMID: 33912740 DOI: 10.1016/j.ekir.2020.12.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 18 |
Eren Sadioglu R, Eyupoglu S, Erdogmus S, Kumru Sahin G, Yoruk F, Kutlay S, Keven K, Erturk S, Sengul S. Infectious Complications in Patients with Primary Glomerulonephritis over 10 Years: A Single-Center Experience in Turkey. Kidney Dis 2021;7:57-66. [DOI: 10.1159/000510153] [Reference Citation Analysis]
|
| 19 |
Agaronyan AG, Vashurina TV, Dmitrienko SV, Voznesenskaya TS, Komarova OV, Zrobok OA, Ryaposova AB, Ananin PV, Fisenko AP, Tsygin AN. Safety and efficacy of mycophenolate mofetil as first-line immunosuppressive therapy in children with steroid-dependent nephrotic syndrome. RPJ 2020;23:360-364. [DOI: 10.18821/1560-9561-2020-23-6-360-364] [Reference Citation Analysis]
|
| 20 |
Chao S, Xu Q, Dong S, Guo M, Liu X, Cheng X. Polygala fallax Hemsl combined with compound Sanqi granules relieves glomerulonephritis by regulating proliferation and apoptosis of glomerular mesangial cells. J Int Med Res 2020;48:300060519894124. [PMID: 32000547 DOI: 10.1177/0300060519894124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 21 |
Han Y, Huang Z, Zhang H, He L, Sun L, Liu Y, Liu F, Xiao L. Nocardiosis in glomerular disease patients with immunosuppressive therapy. BMC Nephrol 2020;21:516. [PMID: 33243202 DOI: 10.1186/s12882-020-02179-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 22 |
Chang D, Cheng Y, Luo R, Zhang C, Zuo M, Xu Y, Dai W, Li Y, Han M, He X, Ge S, Xu G. The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy. Int Urol Nephrol 2021;53:523-30. [PMID: 33113085 DOI: 10.1007/s11255-020-02651-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 23 |
Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Viecelli AK, Dunn L, Harris D, Johnson DW, Kerr PG, Laboi P, Ryan J, Shen JI, Ruiz L, Wang AY, Lee AHK, Fung S, Tong MK, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Tong A; SONG-GD Investigators. Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clin J Am Soc Nephrol 2020;15:673-84. [PMID: 32354728 DOI: 10.2215/CJN.13101019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 24 |
Zhao J, Liu Z. Treatment of nephrotic syndrome: going beyond immunosuppressive therapy. Pediatr Nephrol 2020;35:569-79. [PMID: 30904930 DOI: 10.1007/s00467-019-04225-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 25 |
Rayner HC, Thomas ME, Milford DV. Immunology: Serological Tests That Help Diagnose Kidney Diseases. Understanding Kidney Diseases 2020. [DOI: 10.1007/978-3-030-43027-6_17] [Reference Citation Analysis]
|
| 26 |
Lutz J, Rieke A. Prophylaktische Behandlung von Patienten mit medikamentöser Immunsuppression. Nephrologe 2019;14:393-403. [DOI: 10.1007/s11560-019-0365-4] [Reference Citation Analysis]
|
| 27 |
Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
|
| 28 |
Kestenbaum BR, Seliger SL. Commentary on Complications of Immunosuppressive Treatments for Glomerulonephritis. CJASN 2018;13:1276-1277. [DOI: 10.2215/cjn.07610618] [Reference Citation Analysis]
|
